Branded Medicines & Biologic Therapies

Own commercial drug franchises whose demand depends more on patient treatment than on AI capital spending. Drugmakers' recent relative strength and cash generation offer a differentiated position against QQQ's technology exposure, while upcoming earnings can test whether operating performance supports that strength. Over the holding period, patent erosion, pipeline disappointments and premium valuations remain the principal risks. Launch basket (equal weight): ABBV, AMGN, MRK, LLY, JNJ, GILD, PFE Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.